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Abstract
Background: Preservation of human skin fibroblasts and keratinocytes is essential for the creation of skin tissue
banks. For successful cryopreservation of cells, selection of an appropriate cryoprotectant agent (CPA) is imperative.
The aim of this study was to identify CPAs that minimize toxic effects and allow for the preservation of human
fibroblasts and keratinocytes in suspension and in monolayers.
Results: We cryopreserved human fibroblasts and keratinocytes with different CPAs and compared them to fresh,
unfrozen cells. Cells were frozen in the presence and absence of hydroxyethyl starch (HES) or dimethyl sulfoxide
(DMSO), the latter of which is a commonly used CPA known to exert toxic effects on cells. Cell numbers were
counted immediately post-thaw as well as three days after thawing. Cellular structures were analyzed and counted
by labeling nuclei, mitochondria, and actin filaments. We found that successful cryopreservation of suspended or
adherent keratinocytes can be accomplished with a 10% HES or a 5% HES, 5% DMSO solution. Cell viability of
fibroblasts cryopreserved in suspension was maintained with 10% HES or 5% HES, 5% DMSO solutions. Adherent,
cryopreserved fibroblasts were successfully maintained with a 5% HES, 5% DMSO solution.
Conclusion: We conclude that skin tissue cells can be effectively cryopreserved by substituting all or a portion of
DMSO with HES. Given that DMSO is the most commonly used CPA and is believed to be more toxic than HES,
these findings are of clinical significance for tissue-based replacement therapies. Therapies that require the use of
keratinocyte and fibroblast cells, such as those aimed at treating skin wounds or skin burns, may be optimized by
substituting a portion or all of DMSO with HES during cryopreservation protocols.
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Background
Tissue engineering employs cells, biomaterials, and en-
gineering to repair damaged tissue, replace missing tis-
sue, and/or enhance the function of existing tissue [1].
Tissue engineering shows particular promise for victims
of skin wounds and skin burns. One clinical approach
for these patients is tissue-based replacement therapy,
which can utilize cryopreserved dermal fibroblast and
keratinocyte cells to repair human skin [2]. Cryopreser-
vation, by providing on demand, pretested cells pro-
duced in large, standardized batches, has many clinical
advantages. This therapeutic approach hinges on a cryo-
preservation protocol which optimally preserves the
health and function of skin fibroblasts and keratinocytes.
There is an unmet need for the optimization and de-
velopment of more efficient protocols that preserve cel-
lular integrity. In order to enhance cell survival during
and after cryopreservation, cryoprotectant agents (CPA)
are used. Many standard cryopreservation methods
utilize fetal calf serum (FCS) and/or dimethyl sulfoxide
(DMSO). While effective, FCS is limited in that it is an
animal product and therefore has a probability of con-
tamination (e.g., with bacteria, viruses, or prions) [3].
DMSO is the most standard CPA used but is disadvan-
taged in that it exhibits toxicity to cells in vitro as well
as in patients following clinical application. At low con-
centrations, DMSO thins cell membranes and increases
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their fluidity [4]. At higher concentrations, DMSO in-
duces the formation of transient water pores and can
prompt disintegration of the lipid bilayer [4]. Clinically,
the infusion of peripheral blood progenitors cryopre-
served using DMSO was reported to cause minor to
moderate toxicity in patients and the grade of toxicity
was correlated with the amount of DMSO present in the
transplanted graft [5]. Symptoms of toxicity included
vomiting, nausea, hypotension, and hypertension with
tachycardia [5]. While the most common toxic side ef-
fects associated with DMSO following transplantation
affect the respiratory and cardiovascular systems [6],
neurotoxicity following infusion of DMSO-
cryopreserved peripheral blood stem cells has also been
reported [7]. DMSO-associated toxicity in adult and
pediatric recipients of transplanted, cryopreserved cells
has been reported by numerous laboratories [8–13].
Hydroxyethyl starch (HES) is another CPA that is used
as a plasma substitute in the clinical setting for the treat-
ment of blood loss caused by hemorrhage, burns, and
other tissues injuries [14, 15]. When used at reasonable
concentrations, HES is free of side effects and appears to
be less toxic than DMSO [16–19]. There are several
publications that illustrate the use of HES in cell cryo-
preservation. HES has been previously used to cryopre-
serve keratinocytes [20, 21], islets [22], red blood cells
[23, 24], peripheral blood stem cells [25, 26], and other
cell types [27, 28]. The addition of HES to the CPA solu-
tion has been reported to increase the recovery and via-
bility rate after freezing [21]. In our recent work, we
successfully cryopreserved rat mesenchymal stem cells
using a 5% DMSO, 5% HES solution [29]. Like any other
CPA, the efficacy of HES in cryopreservation might de-
pend on the freezing protocols employed, the techniques
and materials used, and the cell type being preserved.
In the present study we compare different CPA solu-
tions where DMSO was either reduced or substituted
with HES. Following cryopreservation and thawing in
different CPAs, we analyzed viability and proliferation of
the keratinocyte cell line HaCaT, the fibroblast cell line
BJ, and primary foreskin fibroblasts. To our knowledge,
no group has yet tested the ability of HES to cryopre-
serve skin fibroblasts. We find that successful cryo-
preservation of both keratinocytes and fibroblasts can be
achieved by using HES as a CPA.
Methods
Cell sources
Primary human fibroblast cells were isolated from fore-
skin tissue obtained from the Children’s Hospital in
Leipzig, Germany. Ethical approval was obtained from
the University of Leipzig Ethics Commission. Written
consent was obtained from all patients regarding sample
collection. The human keratinocyte cell line HaCaT was
purchased from Cell Lines Service while the human
fibroblast cell line BJ was obtained from ATCC. Consent
was obtained from the patients’ parents/guardians and
the consent was informed.
Cell culture
HaCaT, BJ, and primary human fibroblast cells were cul-
tured in DMEM 1X containing high glucose (Gibco)
supplemented with 1% penicillin/streptomycin (Gibco)
and 10% FCS (Perbio). Cells were trypsinized at 90%
confluency with trypsin/EDTA 1X (Gibco) and centri-
fuged for 5 min at 1000 rpm prior to subsequent cryo-
preservation or subculture.
Cryopreservation procedure
As we have done previously [29, 30], different CPA com-
binations containing DMSO (Sigma), serum (Hyclone),
HES (Serumwerke), and/or DMEM (Gibco) were used to
generate desired cryosolutions (Table 1). A controlled-
rate freezing system (Thermo Scientific Model 7452
Series) was used to cryopreserve the cells. Detailed cryo-
preservation protocols and procedures for cryopreserv-
ing HaCaT, BJ, and primary human fibroblast cells have
been described in our previous work [30]. Fresh, non-
cryopreserved cells were used as a control for each ex-
periment. Fresh cells for monolayer cryopreservation
were seeded at 50,000 cells per well in a 24-well plate
and subjected to 3 additional days in culture. For cells
cryopreserved in suspension, fresh cells were seeded at
10,000 cells per well in a 24-well plate and cultivated for
3 days.
Post-thaw cell count and MTT Assay
The protocol employed for post-thaw cell counts as well
as use of the MTT assay has been described in our pre-
vious work [30]. Media was not changed and cells were
not re-plated during the three-day post-thaw period.
Prior to measuring cell viability, dead cells were removed
by replacing the medium with fresh medium containing
MTT.
Cellular staining
Mitochondria were stained using MitoTracker® CMX-
Ros (Invitrogen). A stock of 1 mM MitoTracker was
Table 1 Cryoprotectant solutions
Cryoprotectants
10% DMSO + 90% FCS
5% DMSO + 95% FCS
5% DMSO + 5% HES + 90% FCS
10% HES + 90% FCS
10% HES + 90% DMEM
10% DMSO + 90% DMEM
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diluted to 200 nM in standard culture media. Media was
removed from the cells and replaced with media contain-
ing 200 nM MitoTracker. Cells were incubated for 30 min
at 37 °C, washed once with PBS 1X, and fixed with 4%
paraformaldehyde (PFA) for 15 min at 4 °C. Cells were
washed three times with PBS 1X and subsequently stained
for actin and nuclei using phalloidin (1:1000; Invitrogen)
and DAPI (1:10000; Sigma), respectively. Cells were
stained in PBS 1X containing 1% Triton-X for 20 min at
room temperature. Cells were washed once with PBS 1X
and observed under a fluorescent microscope. Pictures
were taken using a Leica System.
Flow cytometry
We utilized flow cytometry to quantify the cellular staining
of mitochondria and actin. Following mitochondrial stain-
ing using MitoTracker, cells were trypsinized with trypsin/
EDTA 1X and centrifuged at 1000 rpm for 5 min. Stained
cells were subsequently fixed with 4%PFA for 15 min at 4 °
C and then washed twice with PBS 1X. Then, cells were
stained with phalloidin and washed twice with PBS 1X.
Samples were then run on a BD Accuri C6 Flow Cytometer
(BD Biosciences) and 10,000 cells were counted. Samples
were analyzed using FCS Express Software.
Statistics
For each experiment involving BJ and HaCaT cells, the
presented data represents the mean of 3–5 independent
experiments. For each experiment involving primary fi-
broblasts, the presented data represents the mean of 3–5
independent donors. Error bars represent the standard
error of the mean (SEM). SigmaPlot software was used
to perform one way analysis of variance (ANOVA)
followed by Tukey’s test. Statistical significance was de-
fined as p < 0.05.
Results
Post-thaw cell counts of human keratinocytes and
fibroblasts following cryopreservation in different CPA
solutions
As described in the Methods, HaCaT cells in either sus-
pension (Fig. 1a) or in monolayers (Fig. 1b) were cryo-
preserved using different combinations of the CPAs
DMSO, HES, and FCS (Table 1). Cell counts were made
three days post-thaw and compared to the number of
cells in fresh, unfrozen cells (Fig. 1).
For HaCaT cells cryopreserved in suspension, the cell
number was statistically comparable between fresh cells
and cells thawed in various CPA combinations (Fig. 1a).
For adherent HaCaT cells, the cell number was signifi-
cantly lower in cells cryopreserved in a 10% HES, 90%
DMEM solution than in cells cryopreserved in either a
5% DMSO, 95% FCS solution or a 10% DMSO, 90%
DMEM solution (Fig. 1b).
For BJ cells cryopreserved in suspension, cell counts
were statistically comparable between fresh BJ cells and
Fig. 1 Cryopreservation of HaCaT keratinocyte cells using different cryoprotectants. HaCaT cells were cryopreserved in different cryoprotective
solutions. The total number of cryopreserved HaCaT cells in suspension a or in adherent monolayers b was counted 3 days after thawing. As a
comparison, fresh HaCaT cells were counted. * indicates p < 0.05
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BJ cells thawed in various CPA solutions (Fig. 2a). In
contrast, adherent BJ cells cryopreserved in a 10%
DMSO, 90% FCS solution, a 10% HES, 90% FCS solu-
tion, or a 10% HES, 90% DMEM solution showed signifi-
cantly reduced cell counts compared to fresh cells
(Fig. 2b). The 5% DMSO, 95% FCS solution, the 5%
DMSO, 5% HES, 90% FCS solution, and the 10% DMSO,
90% DMEM solution displayed significantly higher cell
counts than the 10% HES, 90% FCS and 10% HES, 90%
DMEM solutions (Fig. 2b).
The cell number for primary fibroblasts frozen in
suspension was significantly reduced for the 10%
HES, 90% FCS solution compared to fresh cells
(Fig. 3a). All other solutions exhibited comparable cell
counts to fresh cells (Fig. 3a). Regardless of the CPA
solution used, all cryopreserved, adherent primary fi-
broblasts showed a significantly reduced cell number
compared to unfrozen cells (Fig. 3b). Table 2 summa-
rizes the total cell numbers for HaCaT, BJ, and pri-
mary fibroblast cells 3 days post-thaw.
For both HaCaT (Fig. 4a) and BJ (Fig. 4b) cells, no
significant differences in percentage cell viability were
observed immediately post-thaw on Day 0. The only
significant difference observed was in primary fibro-
blast cells, where cells frozen in a 10% HES, 90%
DMEM solution showed a significantly reduced cell
viability (p = 0.018) compared to cells frozen in a 5%
DMSO, 95% FCS solution (Fig. 4c).
Cellular staining of human keratinocytes and fibroblasts
following cryopreservation in different CPA solutions
Cellular integrity of HaCaT, BJ, and primary fibroblasts
cells preserved as monolayers was further assessed via
cellular staining of nuclei, actin, and mitochondria fol-
lowing cryofreezing using different CPA solutions.
We first compared the immunofluorescence staining
of HaCaT cells cryopreserved as monolayers to fresh
HaCaT cells (Fig. 5). We found that mitochondrial
and actin fluorescence were normal or near-normal in
fresh cells as well as in thawed cells cryopreserved
with a 10% DMSO and 90% FCS solution, a 5%
DMSO, 5% HES, and 90% FCS solution, or a 10%
HES and 90% FCS solution. The actin and mitochon-
drial staining was anomalous or reduced in many ker-
atinocytes cryopreserved with a 10% HES and 90%
DMEM solution (Fig. 5).
Fresh, BJ cells or BJ cells cryopreserved in a 10%
DMSO and 90% FCS solution or a 5% DMSO, 5% HES,
and 90% FCS solution showed normal actin staining
(Fig. 6). BJ cells cryopreserved in either solution exhib-
ited slightly odd mitochondrial staining compared to
fresh cells. Both actin and mitochondria appeared
Fig. 2 Cryopreservation of BJ fibroblast cells using different cryoprotectants. BJ cells were cryopreserved in different cryoprotective solutions. The
total number of cryopreserved BJ cells in suspension a or in adherent monolayers b was counted 3 days after thawing. As a comparison, fresh BJ
cells were counted. * indicates p < 0.05
Naaldijk et al. BMC Biotechnology  (2016) 16:85 Page 4 of 11
abnormal or absent in BJ cells cryopreserved in 10%
HES and 90% FCS or 10% FCS and 90% DMEM solu-
tions (Fig. 6).
Fresh, primary fibroblasts grown in monolayers
showed robust staining for actin and mitochondria
(Fig. 7). Although the overall cell numbers were sig-
nificantly reduced (Fig. 3), actin and mitochondria ap-
peared normal or well-nigh normal in adherent,
primary fibroblasts cryopreserved with a 10% DMSO,
90% FCS solution or a 5% DMSO, 5% HES, 90% FCS
solution (Fig. 7). Both actin and mitochondrial stain-
ing were absent or appeared dysfunctional in primary
fibroblasts cryopreserved with solutions containing
10% HES (Fig. 7).
Figure 8 summarizes the immunofluorescence data for
HaCaT, BJ, and primary fibroblast cells. The percentage
of cells with coherent staining for actin and mitochon-
dria was significantly reduced in HaCaT cells cryopre-
served in a 10% HES and 90% DMEM solution (Fig. 8a).
Significantly fewer BJ cells cryopreserved in a 10% HES,
90% FCS or a 10% HES, 90% DMEM showed staining
for actin and mitochondria (Fig. 8b). For primary fibro-
blast cells, a statistically significant reduction in percent
staining for actin and mitochondria was observed for
Fig. 3 Cryopreservation of primary fibroblast cells using different cryoprotectants. Primary fibroblast cells were cryopreserved in different
cryoprotective solutions. The total number of cryopreserved primary fibroblast cells in suspension a or in adherent monolayers b was counted
3 days after thawing. As a comparison, fresh primary fibroblast cells were counted. * indicates p < 0.05
Table 2 Cell viability of each cryopreservation solution for both keratinocytes and fibroblasts on Day 3. Numbers are reported as
mean cell number








10% HES + 90%
DMEM
10% DMSO + 90%
DMEM
Fresh
HaCaT Suspension 93328 217208 117635 88089 71273 103816 70383
HaCaT Adherent 360294 436032 244156 151272 80313 376274 177079
BJ Suspension 100002 130181 107568 76172 40912 131993 54945
BJ Adherent 80448 168692 123244 14801 15238 189289 202214
Primary Fibroblast
Suspension
77990 73114 53455 37670 65406 63977 136237
Primary Fibroblast
Adherent
60997 58264 57475 14271 39625 23652 36170
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cells cryopreserved in a 10% HES, 90% DMEM solution.
A reduction was also observed in primary fibroblast cells
cryopreserved in a 10% HES, 90% FCS solution, but this
reduction was not statistically significant (Fig. 8c).
Discussion
Clinical approaches in regenerative medicine frequently
involve the transplantation of cells, tissue constructs,
and organs [31]. While many studies have worked to
optimize the culturing of live cells prior to transplant-
ation [32–34], a major obstacle in this field is the distri-
bution and timing of finite products for clinical use [35].
As allogenic products are becoming more frequently
used, it is paramount to optimize the long-term storage
of cells and tissues to help minimize clinical costs and
make the distribution easier.
We and others have demonstrated that the successful
cryopreservation of different human cell types can be ac-
complished using HES alone or in combination with
DMSO [16]. It was previously shown by Pasch et al. that
HES can be used to optimally cryopreserve human kera-
tinocytes in suspension and in monolayers [20, 21]. Our
data for HaCaT cells corroborate these findings, showing
that both cell numbers (Fig. 1) and cellular structures
(Fig. 8) are comparable to fresh cells following cryo-
preservation with HES. Table 3 summarizes the optimal
cryopreservation solution containing HES identified for
each cell type. For keratinocytes cryopreserved in either
suspension or in monolayers, both the 5% DMSO, 5%
HES, 90% FCS and the 10% HES, 90% FCS solutions
maintained cell viability (Table 3).
We previously identified the ideal freezing protocols to
use for the cryopreservation of human keratinocytes and
fibroblasts [30]. To our knowledge, however, no group
has compared cryopreservation efficacy in fibroblasts
preserved with HES versus other CPAs. As assessed
by measuring cell numbers (Fig. 2) and analyzing nu-
clei, actin, and mitochondria (Fig. 8), cryopreservation
of BJ fibroblasts in suspension was successfully
achieved using a 5% DMSO, 5% HES, 90% FCS or a
10% HES, 90% FCS solution (Table 3). BJ cells in
monolayers were cryopreserved well in a 5% DMSO,
5% HES, 90% FCS solution (Table 3). In contrast, pri-
mary fibroblasts in monolayers showed decreased cell
viability when cryopreserved in any solution contain-
ing HES (Figs. 3 and 8). Primary fibroblasts in sus-
pension could be successfully cryopreserved in a 5%
DMSO, 5% HES, 90% FCS solution (Table 3).
Fig. 4 Viability of cryopreserved HaCaT, BJ, and primary fibroblast cells immediately post-thaw on Day 0. HaCaT, BJ, and primary fibroblast cells
were cryopreserved in different cryoprotective solutions. Immediately post-thaw on Day 0, percent cell viability was calculated for each cell type
and condition. * indicates p < 0.05
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Fig. 5 Cellular staining of HaCaT keratinocyte cells preserved as a monolayer. Representative immunofluorescence images are shown for
cryopreserved HaCaT cells preserved as monolayers in different cryoprotective solutions. Three days after thawing, cells were stained for nuclei,
actin, and mitochondria. For comparison, nuclei, actin, and mitochondria were stained in fresh HaCaT cells
Fig. 6 Cellular staining of BJ fibroblast cells preserved as a monolayer. Representative immunofluorescence images are shown for cryopreserved
BJ cells preserved as monolayers in different cryoprotective solutions. Three days after thawing, cells were stained for nuclei, actin, and
mitochondria. For comparison, nuclei, actin, and mitochondria were stained in fresh BJ cells
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Fig. 7 Cellular staining of primary fibroblast cells preserved as a monolayer. Representative immunofluorescence images are shown for
cryopreserved primary fibroblast cells preserved as monolayers in different cryoprotective solutions. Three days after thawing, cells were stained
for nuclei, actin, and mitochondria. For comparison, nuclei, actin, and mitochondria were stained in fresh primary fibroblast cells
Fig. 8 Quantification of actin and mitochondria labeling by flow cytometry. HaCaT, BJ, and primary fibroblast cells were cryopreserved in different
cryoprotective solutions. Three days after thawing, cells were stained for nuclei, actin, and mitochondria. Flow cytometry analysis was performed
and the percentage of HaCaT a, BJ b, and primary fibroblast c cells showing staining for actin and mitochondria was counted. * indicates p < 0.05
compared to fresh cells
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Significant differences in cell viability were observed
between HaCaT, BJ, and primary fibroblast cells (Figs. 1,
2, and 3). During cryopreservation, cells and tissues
must traverse a lethality zone of temperature (−15 to
−60 °C) when being frozen down to very low tempera-
tures and then once again when being thawed [36].
While passing through this zone, cells and tissues must
endure the damaging effects of vitrification, cold shock,
osmotic injury, and intracellular ice formation [36]. Our
data indicate that different cell types are uniquely cap-
able of resisting and repairing damage that occurs during
cryopreservation and subsequent thawing. Of particular
interest is that the viability of BJ cell line fibroblasts
(Fig. 2) was notably higher than the viability of primary
fibroblasts (Fig. 3). One possibility is that, since BJ cells
are commercially available and routinely undergo freeze-
thaw cycles, this cell line has undergone a selection for
cells that can robustly withstand cryopreservation. In
contrast, primary fibroblasts derived from donors have
had no such opportunity to undergo a selection for cells
especially resistant to freezing-induced damage. HaCaT
cells seemed to cryopreserve more efficiently than fibro-
blast cells. Since keratinocytes are smaller in size than fi-
broblasts [37, 38] and cells tend to shrink due to
osmosis during cryopreservation [39], a potential explan-
ation for this is difference is that fibroblasts undergo
more drastic cell shrinkage during freezing and subse-
quent thawing. This proposed increase in cell shrinkage
stress may result in decreased viability.
As we have previously found with mesenchymal
stem cells [29], predominantly negligible differences
in cell viability were found immediately post-thawing
at Day 0 for HaCaT, BJ, and primary fibroblast cells
(Fig. 4). This is most likely explained by the fact that
cryopreservation-induced apoptotic cell death has
been estimated to take between 6 and 24 h [40] and
can still be observed 24-h post-thaw [41]. We chose
not to include additional time points beyond Day 3
as, in our previous work with mesenchymal stem
cells [29], we found minimal differences in cell via-
bility between Day 3 and Day 14-post-thaw. Interest-
ingly, the cell number for some cryopreservation
conditions in HaCaT cells was higher than the con-
trol, fresh cells (Fig. 1). It is possible that, for certain
cell types, specific CPA solutions promote viability
and growth over fresh cells. The general variations
in cell number are due to each cell type having a
unique proliferation and survival rate in adherent vs.
suspension conditions.
It should be noted that, while HES is thought to be
clinically safe [16], toxic effects of HES have been noted
in the literature. Singbartl et al. reported that cryopreser-
vation of erythrocytes using HES in lieu of glycerol led
to the development of transient rheological alterations,
including an altered membrane skeleton [42]. A system-
atic review assessing the use of HES for fluid manage-
ment found that HES may increase the risk of acute
renal failure in patients with sepsis [43]. This risk ap-
peared to increase with higher doses of HES [43]. While
HES has been reported in association with adverse ef-
fects, a much higher of concentration of HES is required
to induce toxicity than DMSO [16].
A randomized phase III clinical trial found that autolo-
gous blood stem cell transplantation could be effectively
accomplished using cells cryopreserved in a 5% DMSO,
6% HES solution or a 10% DMSO solution. While two
patients infused with cells cryopreserved with DMSO
displayed serious neurological toxicity, none of the pa-
tients who received DMSO/HES cryopreserved cells
showed any serious toxicities [44]. Given concerns of
DMSO toxicity and the low cost of HES, the authors of
that trial suggested replacing a portion of DMSO with
HES when cryopreserving cells [44]. A literature review
summarizing the known data regarding HES corrobo-
rates this trial data, suggesting that HES is less toxic
than DMSO and that, at low concentrations, HES is
clinically safe [16]. Although the data seem to suggest
that DMSO is more toxic than HES, further studies
should be performed to specifically compare the clinical
safety of HES vs DMSO in patients transplanted or in-
fused with cryopreserved cells.
While we feel that the data contained herein are novel
and significant, there are limitations of this work. Ideally,
the concentration of FCS would be decreased or FCS
would be omitted entirely since it is a derived animal
product and therefore susceptible to contamination. Al-
though we did include two different CPA combinations
that omitted FCS entirely (10% HES, 90% DMEM and
10% DMSO, 90% DMEM), the remaining CPA combina-
tions only featured two different concentrations of FCS
– 90% and 95%. Future studies are warranted to assess
whether or not such high concentrations of FCS are re-
quired when using HES as a CPA. Moreover, it would be
of interest to measure cell viability and cryopreservation
Table 3 The optimal cryopreservation solutions containing HES identified for keratinocytes and fibroblasts
Cell Type Suspension Monolayer
HaCaT 5% DMSO + 5% HES + 90% FCS or 10% HES + 90% FCS 5% DMSO + 5% HES + 90% FCS or 10% HES + 90% FCS
BJ 5% DMSO + 5% HES + 90% FCS or 10% HES + 90% FCS 5% DMSO + 5% HES + 90% FCS
Primary fibroblasts 5% DMSO + 5% HES + 90% FCS N/A
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efficiency by investigating other parameters, such as cell
viability, recovery, and metabolism. Growth rates, cell-
substrate attachment, and gene and protein analyses
would also be valuable to quantify. While we did not as-
sess these parameters in this manuscript, we are inter-
ested in building off the present study to do so with our
future investigations.
Conclusions
In sum, we show that both human keratinocytes and fi-
broblasts can be effectively cryopreserved using HES as
a CPA. That fibroblasts can be preserved in a HES-
containing solution is, to our knowledge, a novel and
previously unreported finding. Given that DMSO is the
most commonly used CPA and is believed to be more
toxic than HES, these findings are of significance for
tissue-based replacement therapies. Therapies that re-
quire the use of keratinocyte and fibroblast cells, such as
those aimed at treating skin wounds or skin burns, may
be optimized by substituting a portion or all of DMSO
with HES during cryopreservation protocols.
Abbreviations
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HES: Hydroxyethyl starch
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